Silo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 73.3% and free cash flow grew 39.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SILO
Silo Pharma, Inc. (SILO) Altman Z-score
Silo Pharma, Inc.'s Altman Z-score for fiscal 2025 is −3.06, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −3.06 | 0.20 |
| FY2024 | −3.26 | (2.43) |
| FY2023 | −0.83 | (3.63) |
| FY2022 | 2.80 | (2.74) |
| FY2021 | 5.55 | (458.87) |
| FY2019 | 464.42 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.89 | — | 1.06 | |
| Retained earnings / total assets | (2.56) | — | −3.59 | |
| EBIT / total assets | (0.56) | — | −1.86 | |
| Market value of equity / total liabilities | 2.19 | — | 1.32 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Distress zone | −3.06 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −1.23 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| PPBT Purple Biotech Ltd. Sponsored ADR compare | 5.5× |
| SILO Silo Pharma, Inc. | −3.1× |
| VRAX Virax Biolabs Group Limited compare | −5.3× |
| CLSDQ Clearside Biomedical, Inc. compare | −22.1× |
| TRVN Trevena, Inc. compare | −22.1× |
| OGEN Oragenics, Inc. compare | −67.3× |
| BRTX Biorestorative Therapies, Inc. compare | −71.0× |
| GNPX GENPREX compare | — |
| KAPA Kairos Pharma, Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets